Pixium Vision’s research partner presents at ARVO three posters on PRIMA, a tiny wireless subretinal implant

Regulatory News:

Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced that its research partner presented three PRIMA related posters at the Association for Research in Vision and Ophthalmology (ARVO).

Professor Daniel Palanker from the Department of Ophthalmology and Hansen Experimental Physics Laboratory and academic partner of Pixium Vision said: "Pre-clinical results of the wireless subretinal photovoltaic arrays we have developed are very encouraging. In the presented posters we evaluate activation mechanisms and characteristics of prosthetic vision, including contrast sensitivity and dynamic range, compared to normal vision. We also describe interaction of prosthetic and natural vision. This is very important for restoration of sight in patients with residual peripheral vision such as in Age related Macular Degeneration.”

The three preclinical posters on PRIMA, a wireless subretinal photovoltaic implant, are:

• Interaction between normal and prosthetic vision in a model of local retinal degeneration
  Sunday 3 May 2015 at 1:30-3:15 (Poster board #: D0150; Abstract Number: 756 - D0150)

• Mechanisms mediating subretinal photovoltaic activation of ganglion cells
  Tuesday 5 May 2015 at 11:00-12:45 (Poster board #: A0087; Abstract Number: 3238 - A0087)

• Contrast sensitivity in photovoltaic prosthesis-activated degenerate retina
  Tuesday 5 May 2015 at 11:00-12:45 (Poster board #: A0088; Abstract Number: 3239 - A0088)

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision’s VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS^® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. The approval of IRIS^® is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX
IRIS^® is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).